Global brokerage JPMorgan, too, has upgraded the stock from 'Underweight' to 'Neutral', and has raised target price from Rs 140 to Rs 190.
"Incremental disclosures on balance sheet/ZEE5 coupled with management commitment towards improving FCF and further strengthening of the Board are steps in the right direction, implying downside protection from the current depressed levels. Further we believe the stock can re-rate significantly (trading at 10x F22E P/E vs past 1yr median of 15x), if management delivers on the stated commitments," it said in a report dated August 19.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)